Matt Meyerson headshot

Matt Meyerson

Charles A. Dana Chair in Human Cancer Genetics, Dana-Farber Cancer Institute
Professor of Genetics and Medicine, Harvard Medical School
Director, Center for Cancer Genomics, Dana-Farber Cancer Institute
Dana Farber Cancer Institute
617-632-4377
Meyerson Lab
Phosphorylation of the menin tumor suppressor protein on serine 543 and serine 583.
Authors: Authors: MacConaill LE, Hughes CM, Rozenblatt-Rosen O, Nannepaga S, Meyerson M.
Mol Cancer Res
View full abstract on Pubmed
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.
Authors: Authors: Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG, Kuefer R, Vessella R, Sun XW, Meyerson M, Lee C, Sellers WR, Chinnaiyan AM, Rubin MA.
Cancer Res
View full abstract on Pubmed
C/EBP alpha mutations in lung cancer.
Authors: Authors: Costa DB, Dayaram T, D'Alo F, Wouters BJ, Tenen DG, Meyerson M, Tsao MS, Halmos B.
Lung Cancer
View full abstract on Pubmed
Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents.
Authors: Authors: Lynch TJ, Adjei AA, Bunn PA, Eisen TG, Engelman J, Goss GD, Haber DA, Heymach JV, Jänne PA, Johnson BE, Johnson DH, Lilenbaum RC, Meyerson M, Sandler AB, Sequist LV, Settleman J, Wong KK, Hart CS.
Clin Cancer Res
View full abstract on Pubmed
Genomic approaches to lung cancer.
Authors: Authors: Thomas RK, Weir B, Meyerson M.
Clin Cancer Res
View full abstract on Pubmed
Epidermal growth factor receptor mutation testing in the care of lung cancer patients.
Authors: Authors: Sequist LV, Joshi VA, Jänne PA, Bell DW, Fidias P, Lindeman NI, Louis DN, Lee JC, Mark EJ, Longtine J, Verlander P, Kucherlapati R, Meyerson M, Haber DA, Johnson BE, Lynch TJ.
Clin Cancer Res
View full abstract on Pubmed
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
Authors: Authors: Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jänne PA.
Clin Cancer Res
View full abstract on Pubmed
Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.
Authors: Authors: Shimamura T, Ji H, Minami Y, Thomas RK, Lowell AM, Shah K, Greulich H, Glatt KA, Meyerson M, Shapiro GI, Wong KK.
Cancer Res
View full abstract on Pubmed
Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing.
Authors: Authors: Thomas RK, Nickerson E, Simons JF, Jänne PA, Tengs T, Yuza Y, Garraway LA, LaFramboise T, Lee JC, Shah K, O'Neill K, Sasaki H, Lindeman N, Wong KK, Borras AM, Gutmann EJ, Dragnev KH, DeBiasi R, Chen TH, Glatt KA, Greulich H, Desany B, Lubeski CK, Brockman W, Alvarez P, Hutchison SK, Leamon JH, Ronan MT, Turenchalk GS, Egholm M, Sellers WR, Rothberg JM, Meyerson M.
Nat Med
View full abstract on Pubmed
Epidermal growth factor receptor (EGFR) mutation testing in non-small cell lung cancer (NSCLC) patients (pts).
Authors: Authors: Sequist LV, Joshi VA, Jänne PA, Fidias P, Muzikansky A, Meyerson M, Haber DA, Kucherlapati R, Johnson BE, Lynch TJ.
J Clin Oncol
View full abstract on Pubmed